September 2022 Expression pattern and clinical significance of beta 2-adrenergic receptor in oral squamous cell carcinoma: an emerging prognostic indicator and future therapeutic target " Purpose: Beta 2-Adrenergic

September 2022 "Research on cancer therapies focuses on processes such as angiogenesis, cell signaling, stemness, metastasis, and drug resistance and inflammation, all of which are influenced by the cellular and molecular microenvironment of the tumor. Different strategies, such as antibodies, small chemicals, hormones, cytokines, and, recently, gene editing techniques, have been tested to reduce the malignancy and generate a harmful microenvironment for the tumor. Few therapeutic agents have shown benefits when administered alone, but a few more have demonstrated clear improvement when administered in combination with other therapeutic molecules. In 2008 (and for the first time in the clinic), the therapeutic benefits of the β-adrenergic receptor antagonist, propranolol, were described in benign tumors, such as infantile hemangioma. Propranolol, initially prescribed for high blood pressure, irregular heart rate, essential tremor, and anxiety, has shown, in the last decade, increasing evidence of its antitumoral properties in more than a dozen different types of cancer. Moreover, the use of propranolol in combination therapies with other drugs has shown synergistic antitumor effects. This review highlights the clinical trials in which propranolol is taking part as adjuvant therapy at single administration or in combinatorial human trials, arising as a good pick and roll partner in anticancer strategies." Read more at the source #DrGPCR #GPCR #IndustryNews

mucosal inflammation via enhancing NLRP3 inflammasome activation in macrophages "The putative medium-chain

, Allergic rhinitis , Antibody-dependent cellular cytotoxicity , Atopic dermatitis , BAM8-22 , BP , Beta chain , Bovine adrenal medulla peptide 8-22 , Bullous pemphigoid , C-C motif chemokine ligand 17 , CCL17 growth factor , Neuromedin U , OSM , OSMRβ , Oncostatin M , Oncostatin-M specific receptor subunit beta and Drug Administration , VIP , Vasoactive intestinal peptide , Voltage-gated sodium channel , gamma chain

< GPCR News < GPCRs in Oncology and Immunology Expression pattern and clinical significance of beta 2 prognostic indicator and future therapeutic target Published date November 1, 2022 Abstract Purpose: Beta

Beaulieu was an associate professor and Canada Research Chair (Tier2) in the Department of Psychiatry Beaulieu has pioneered work establishing a role for Beta-arrestin signaling in the brain in vivo and proteins can act as allosteric modulators of D2R signaling and explores the potential usefulness of beta-arrestins